Response of HIV-infected patients with syphilis to therapy with penicillin or intravenous ceftriaxone by Spornraft-Ragaller, P et al.
february 24, 2011 47 Eu  Ro  PE  an JouR  nal of MEd  I  cal RE  sEaRcH
Abstract
Background: ceftriaxone is commonly used as an alter-
native antibiotic drug in treating syphilis but clinical
data on its efficacy are limited. objective: to evaluate
the  response  of  HIV-infected  patients  with  active
syphilis to treatment with penicillin or ceftriaxone. 
Methods: a retrospective study involving 24 consecu-
tive patients with a positive Veneral disease Research
laboratory test (VdRl) and at least one specific tre-
ponemal test. 12 patients were treated with different
regimens  of  high-dose  penicillin  G  for  at  least  2
weeks. another 12 patients were treated with ceftriax-
one 1-2g per day intravenously for 10-21 days. 
Results: after a median follow up of 18,3 months all
patients of the penicillin-treated group and 11 of 12
ceftriaxone-treated patients showed a ≥ 4-fold decline
in VdRl-titers; 91% of them already within 6 months
after therapy. 
Conclusion: our serological data demonstrate a com-
parable  efficacy  of  currently  recommened  penicillin
and ceftriaxone treatment regimens for active syphilis
in HIV-infected patients. 
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IntRoductIon
syphilis in HIV-infected patients is reported to show a
more severe and accelerated course [1-4] with a higher
risk for progression to neurosyphilis [5, 6]. therefore,
in this population, close monitoring for neurosyphilis
is recommended and in cases of latent syphilis with
unknown  duration,  lumbar  puncture  should  be  per-
formed. since this procedure may be refused, in such
cases high -dose parenteral therapy regimens are fre-
quently  warranted.  once  neurosyphilis  is  excluded,
current European and us-guidelines for treatment of
syphilis make no distinction between patients with or
without HIV-infection [7, 8]. the treatment of choice
for  neurosyphilis  is  intravenous  benzyl  penicillin  G,
which  results  in  treponemicidal  levels  in  the  cere-
brospinal fluid. However, the recommended adminis-
tration of 3-6 doses per day often requires hospitalisa-
tion of the patients. alternative antibiotic substances
are limited; in European guidelines they include oral
therapy  with  doxycycline,  whereas  the  cdc  favours
parenteral therapy with ceftriaxone. only few studies
including a low number  of predominantly HIV-infect-
ed patients with neurosyphilis or latent syphilis have
shown a similar efficacy of ceftriaxone and penicillin
[9-11]. despite of the lack of clinical evidence, ceftri-
axone is commonly used as an alternative in treating
syphilis [12] and therefore, more reports on its efficacy
in this setting are clearly needed.
PatIEnts and MEtHods
Between January 2001 and december 2008, 29 con-
secutive  HIV-infected  patients  with  active  syphilis
were identified at the department of dermatology at
the university Hospital, technical university of dres-
den. diagnosis of syphilis was confirmed by a positive
VdRl and at least one additional specific treponemal
test (tPHa, tPPa, treponema pallidum immunoblot,
IgG-  and  19s-IgM  fluorescence  treponema  absorp-
tion-test). all 29 patients were treated but only 24 pa-
tients with one or more follow up visits were included
in this study. a mean of 7.7 (1-21) serological follow
up  investigations  for  syphilis  per  patient  were  per-
formed; data were collected until 31.5.2009.
all 24 patients were men who had sexual contacts
with  men  (MsM)  with  a  median  age  of  41  (29-57)
years  at  the  time  of  diagnosis  of  syphilis.  Baseline
VdRl ranged from 1:8 to1:512. 21 patients presum-
ably had early syphilis, predominantly at stage II. 17 of
24 patients showed clinical manifestations consistent
with syphilis when seen in our outpatient clinic. In 6
of 24 patients lumbar puncture was performed and in
3 patients neurosyphilis was diagnosed. In 2 patients,
serology  and  history  pointed  to  reinfection;  in  two
other patients reactivation of a previous syphilis infec-
tion  treated  elsewhere  could  not  be  excluded,  as  a
VdRl test prior to the current syphilis episode was
not available (table1). 
12  patients  with  syphilis  were  treated  with  peni-
cillin: 8 subjects received benzathine penicillin 2.4 Mu
intramuscularly (i.m.)  in weekly intervals for 3 weeks
(n = 7) or 2 weeks (n = 1); 2 patients received clemi-
zole penicillin G 1 Mu i.m. daily for 14 or 21 days and
2 patients penicillin G intravenously (i.v.) 3x 10 Mu
daily for 21 days. 12 patients received i.v. ceftriaxone: 8
patients 2g once per day for 10-14 days, 2 patients 2g
for 21 days and another 2 patients 1g for 14 days.
the patients were compared according to treatment
with either penicillin based (n =12) or, more recently,
i.v. ceftriaxone based regimens (n = 12). after treat-
ment, all patients had at least one follow up-investiga-
tion of VdRl, performed between 1 and 19 months
after  completion  of  therapy.  the  median  follow  up
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months for the penicillin group (mean 38.2) and 11.5
months  (mean  21,8)  for  the  ceftriaxone  group  (p  <
0.13). 7 patients in each treatment group received high-
ly  active  antiretroviral  therapy  (HaaRt).  the  mean
cd4+ t cell counts in peripheral blood in all patients
were 358 /μl (24-849) before treatment of syphilis.
serological treatment response was defined as a ≥ 4
fold decrease (or 2 dilutions) in VdRl-titer or rever-
sion of VdRl to nonreactive. neurosyphilis was diag-
nosed when a specific treponemal IgG production in
cerebrospinal fluid (csf) with an Itpa-Index of ≥ 4
(based on tPPa) compared to serum was demonstrat-
ed. syphilis stage I and II was diagnosed in patients
who presented with typical symptoms in our outpa-
tient  clinic.  Most  of  these  cases  were  previously
seronegative with documented seroconversion. Rein-
fection was considered when the VdRl-test rose ≥ 4
fold after previous reversion to negative. Early latent
syphilis  was  assumed  in  asymptomatic  patients  who
had  experienced  symptoms  consistent  with  syphilis
less than a year before diagnosis. Patients without doc-
umented seroconversion and without history of symp-
toms were classified as latent syphilis of unknown du-
ration.
for statistical analysis the two sided Mann whitney
u-test for unpaired samples and fisherﾴs Exact test
were performed (sPss, Version 17).
REsults
24 patients were analyzed; 12 had received penicillin in
various dose regimens mainly i.m. and 12 had been
treated  with  i.v.  ceftriaxone  at  daily  doses  of  2g  in
most cases. 
comparing both treatment groups, the patients did
not differ in respect to age (p = 0.38) or the propor-
tion  receiving  HaaRt.  cases  with  symptomatic
syphilis were slightly more common in the penicillin
group reflecting a greater proportion of primary and
secondary  syphilis.  overall  median  baseline  VdRl
was 1:64 (1:8-1:512) with a tendency to higher titers
in the ceftriaxone group (median 1:64-1:128 ) vs. 1:32
in the penicillin group ( n.s., p = 0.23). the patients of
the ceftriaxone group had higher baseline cd4-t-cell
counts but the difference did not reach statistical sig-
nificance (p = 0.08).  six cases treated with i.m. peni-
cillin could clearly be diagnosed as early syphilis with
documented  seroconversion  or  reinfection,  whereas
ceftriaxone or i.v. penicillin was chosen for treatment
of patients without documented seroconversion (n =
8; 67 % of the patients in the ceftriaxone group) or in
cases with suspected penicillin allergy (n = 3). Herx-
heimerﾴs reactions occurred in some patients with sec-
ondary syphilis but were not monitored consistently,
because patients who refused hospitalisation were giv-
en prophylaxis (50 mg prednisolone).
follow-uP and tREatMEnt REsults
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Table 1. Baseline characteristics.
characteristic Penicillin ceftriaxone p
n = 12 n = 12
age, median years 42      (33-57) 40.5   (29-47) 0,38
follow-up, median months 38,3   (5.5-73) 11.5   (1.5-78.5) 0.13
cd4+ t cell counts, median cells/μl 264    (128-849) 411    (24-707) 0.08
HaaRt, n= 77
Baseline VdRl, median 1:32 1:64-1:128 0.23
Early syphilis n = 11 of 12 (92%) 9 of 12 (75%) 0.59
stage I 21
stage II 66
Early latent 32
neurosyphilis n = 12
Probably late latent, unknown duration, n= 01
clinical signs at presentation, n= 9 of 12 (75%) 7 of 12 (58%) 0.66
Reinfection, n = 20
possible reactivation, n = 02
documented seroconversion, n = 6 of 12 (50%) 4 of 12 (33%) 0.68
lumbar puncture , n = 24
Table 2. treatment results.
Penicillin ceftriaxone p
n = 12 n = 12
≥ 4-fold decrease in VdRl-titer after treatment 12 of 12 11 of 12
within 3 months 5 of 7 (71%) 10 of 11 (91%) 0.52
within 6 months 9 of 10 (90 %)
within 12 months 11 of 11 11 of 12 (92%)
within 20 months 12 of 12
negative VdRl-titer at the end of follow up 6 of 12 4 of 12 0.68
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a first control of VdRl within 3 months after com-
pletion of therapy was available in 11 cases of the cef-
triaxone  group  and  in  7  patients  of  the  penicillin
group.10 of 11 ceftriaxone treated patients showed a
≥  4  fold  decrease  of  VdRl-titers  within  3  months
(median 1,75 months) as well as 5 of 7 cases of the
penicillin group. when the VdRl test was performed
within 6 months after therapy, the percentage of pa-
tients with a 4-fold VdRl decrease rose to 90 % in
the penicillin group (9 of 10 cases). In the remaining
patients, a first VdRl control was available only at
6,5,  7,5,  11 and 19 months after therapy. at that time,
these  patients  showed  already  a  reversion  of  the
VdRl to negative (n = 3) or weakly positive (titer 1:2;
n = 1). within a year after therapy, 22 of 23 patients
showed a serological response to treatment with either
penicillin or ceftriaxone and taken together, 23 of 24
patients  responded  within  20  months.  10  patients
achieved a negative VdRl; 7 in the penicillin group
after a median follow-up of 38,3 months and 3 in the
ceftriaxone  group  after  a  median  follow  up  of  11,5
months. we additionally analyzed 13 patients with a
VdRl being available at approximately one year after
therapy  (13  months  n  =  4;  12  months  n  =  5;  11
months n = 2; 10 months n = 2). 7 patients were treat-
ed with penicillin and 6 patients with ceftriaxone. at
that time, all patients showed a ≥ 8 fold (or 3 dilution)
decline of VdRl or reversion of the VdRl to nega-
tive. the latter occurred in 3 patients with a VdRl
being available after 13 months and in 1 patient after
10  months,  respectively.  only  one  patient  with  pre-
sumably latent neurosyphilis, assigned to the ceftriax-
one group, remained serofast after treatment with ei-
ther i.v. ceftriaxone 2g for 14 days or subsequent i.v.
penicillin for 3 weeks. this patient had been newly di-
agnosed to have both HIV- and syphilis infection at
cd4-t-cell counts of 24/μl. Initial VdRl was 1:16
and tPHa was 1:640 without demonstration of spe-
cific  IgM  (19-s  IgM-fta-aBs-test).  a  previous
syphilis infection was not known. there were no clini-
cal signs of neurosyphilis and no pleocytosis of the
cerebrospinal fluid (csf). However, the Itpa-Index
was 4,7 and the tPHa-Index was 385 compared to
serum (tPHa-Index of 100-500: neurosyphilis proba-
ble), thus indicating specific intrathecal IgG produc-
tion. after treatment with ceftriaxone and stabilisation
of cd4-t-cell counts at 322/ μl under HaaRt, the
second treatment with penicillin G did not significant-
ly influence VdRl- or tPHa-titers. 
Most of the patients (n = 18) could be closely mon-
itored with 3 or more serological follow-up data being
available.  until  the  end  of  follow  up,  no  relapse  of
syphilis was identified in any of the patients. However,
in 2009 two patients acquired an additional syphilis in-
fection with significant rise of specific treponemal and
VdRl titers. one patient had been previously treated
with penicillin and the other one with ceftriaxone. In
both patients, previous VdRl titers had declined to 1:
2 or to nonreactive, respectively. one patient showed
syphilis stage I and gave a history of unprotected sex
4 weeks before development of genital ulcers; the oth-
er  patient  exhibited  a  typical  exanthema  of  syphilis
stage  II.  therefore,  these  additional  episodes  of
syphilis were regarded as reinfections and were not in-
cluded in this study.
dIscussIon
In  concurrent  HIV-infection,  syphilis  may  show  a
more severe course, a more rapid progression to neu-
rosyphilis and higher rates of treatment failure [4, 6,
13]. the magnitude of this risk is not precisely de-
fined. there are some reports on treatment failure af-
ter therapy of early syphilis with benzathine penicillin
[14].  a large randomized, prospective controlled trial
in 541 patients including 101 with HIV-infection as-
sessed enhanced therapy of early syphilis with benza-
thine  penicillin  2,4  Mu  i.m.  plus  amoxicillin  and
probenecid compared to benzathine penicillin alone.
this study was not able to demonstrate an advantage
of  the  enhanced  therapy  [15,  16].  therefore,  most
guidelines for treatment of syphilis in HIV –infected
patients do not substantially differ from those for pa-
tients without HIV-infection [16]. However, some ex-
perts recommend more intensive therapeutic regimens
even for early syphilis in HIV-infection [7] with benza-
thine  penicillin 2,4 Mu in weekly intervals at day 1, 8
and 15 which is in concordance with current Euro-
pean and German Guidelines [8, 17].  the same regi-
men can be used for late latent syphilis or syphilis of
unknown duration if csf examination is normal. If
neurosyphilis is suspected but lumbar puncture is re-
fused, treatment with aqueous i.v. penicillin G is advis-
able. alternative substances for treating neurosyphilis
are scarce: In case of penicillin allergy, according to
European guidelines oral therapy with doxycycline is
considered;  the  cdc  [7]  in  this  situation  proposes
penicillin desensitization or ceftriaxone at a dose of 2g
per day i.m. or i.v. However, clinical data on the effica-
cy of ceftriaxone for treatment of syphilis compared
to standard therapy with penicillin are limited.
In  our  study,  HIV-infected  patients  with  syphilis
were treated with either penicillin or ceftriaxone at rel-
atively high doses based on current treatment guide-
lines described above. In 24 patients we could observe
a comparable effect of both penicillin and ceftriaxone
based  regimens  after  a  median  follow  up  of  18,3
months. all 12 patients treated with penicillin showed
the same treatment response with a ≥ 4 –fold decline
in VdRl-tests as 11 of 12 patients treated with ceftri-
axone.  after  completion  of  treatment  with  ceftriax-
one, 10 of 11 patients (91%) achieved a ≥ 4 –fold de-
cline in VdRl-tests already within 3 months and an-
other patient within 6,5 months. taken together, 11 of
12 patients (92%) responded to therapy with ceftriax-
one after 12 months except for one patient who re-
mained serofast.  after treatment with penicillin, only
5 of 7 patients showed a ≥ 4-fold decline of VdRl
within 3 months. after a follow up of 19,5 months, all
12  patients  treated  with  penicillin  had  shown  a  re-
sponse  to  therapy.  although  most  patients  achieved
treatment response less than 12 months after comple-
tion of therapy, in 13 patients (7 treated with penicillin
and 6 treated with ceftriaxone) the response at approx-
imately one year (10-13 months) after therapy was de-
termined. In all patients, a ≥ 8 fold decline of VdRl
could be observed, thus also indicating similar efficacy
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rapid response to ceftriaxone compared to penicillin;
however, despite of the lack of significant differences
in baseline characteristics, a direct comparison is diffi-
cult:  on  one  hand,  the  patients  in  the  ceftriaxone
group had somewhat higher baseline VdRl-titers to-
gether  with  higher  baseline  cd4-t-cell  counts  and
therefore  might  have  had  a  more  rapid  decrease  of
VdRl ; on the other hand, in this group were also
more patients with unknown duration of syphilis and
a more complicated disease. one patient with proba-
bly late latent neurosyphilis did not respond to treat-
ment with either ceftriaxone or subsequent penicillin.
there exist only few small studies on clinical data
concerning the efficacy of ceftriaxone  for treatment
of syphilis, as recently reviewed by Parkes and stoner
[15, 18]. In a report of smith et al. [9] 24 HIV-infected
patients with asymptomatic syphilis and a rapid plasma
reagin (RPR) titer of ≥ 1:4 were randomized to treat-
ment with either ceftriaxone 1g i.m. (n = 10) or en-
hanced  treatment  with  procaine  penicillin  plus
probenecid for 15 days (n = 14) and were followed up
prospectively (median follow up 32 months for peni-
cillin  and  18  months  for  ceftriaxone):  In  this  study,
only 70 % of procaine penicillin treated patients and
71% of ceftriaxone treated patients showed a ≥ 4 fold
decline in RPR-titers. However, most of the patients
were believed to have late latent syphilis and all were
enrolled before the availability of HaaRt. In another
study of the pre-HaaRt-era on the efficacy of ceftri-
axone 1-2 g per day for 10-14 days in HIV-infected pa-
tients with latent or neurosyphilis there was a response
rate of 65 % in 28 patients treated with ceftriaxone vs.
62% in patients treated with benzathine penicillin [11] .
a more recent study of Marra et al. [10] found that vir-
tually  all  of  59  predominantly  HIV-infected  patients
with  neurosyphilis  showed  a  normalisation  of  csf
white blood cell counts and csf VdRl after various
treatment  regimens  including  ceftriaxone  2g  i.v.  in  7
patients. In a previous randomized pilot study by the
same author [19] evaluating ceftriaxone or penicillin G
for treatment of neurosyphilis in 30 HIV-infected pa-
tients, ceftriaxone was found to be equally effective in
improving csf markers for neurosyphilis and seemed
to be superior concerning decline of serum RPR titers
(80%  vs.  13%  of  the  patients).  follow  up,  however,
was short (3-6 months) in this study and most of the
patients had a history of previous syphilis of which
neurosyphilis  was  prevailing  in  the  penicillin  group.
another randomized study of 28 presumably HIV-neg-
ative patients with primary or secondary syphilis com-
pared treatment with ceftriaxone i.m. or penicillin G
i.m. daily for 2 weeks and found no difference of clini-
cal and serological response. after a maximum follow
up of 12 months all patients achieved at least a 2-fold
dilution decrease in VdRl-titers [20]. the efficacy of
ceftriaxone  for  treatment  of  syphilis  is  also  demon-
strated by a recent report on 3 cases of HIV-infected
patients with neurologic syphilis after treatment of pri-
mary or secondary syphilis with benzathine penicilline
who responded to subsequent therapy with ceftriaxone
[21]. In summary, a review of the literature suggests
that ceftriaxone i.v. or i.m. seems to be similarly effec-
tive for treatment of syphilis as penicillin based regi-
mens which is in concordance with our findings. there
seems to be more experience with ceftriaxone in HIV-
coinfected patients. the higher failure rates previously
reported might be attributable to the unavailability of
HaaRt in some of the earlier studies and to the stage
of syphilis irrespective of the treatment regimen: In
asymptomatic patients with late latent syphilis, reinfec-
tion or syphilis of unknown duration and low titers of
VdRl, serologic follow up is difficult. since most of
our patients had early stages of syphilis, some of them
with  documented  seroconversion,  this  might  explain
the favourable overall response to both ceftriaxone and
penicillin. limitations of our investigation are – as in
some previous studies - the small sample size and the
heterogeneity  of  active  syphilis  stages.  Patients  were
treated with relatively high, but different doses of both
antibiotics  and  follow  up  was  retrospective  and  not
standardized. although not significant, patients treated
with  ceftriaxon  had  higher  baseline  cd4  cell  counts
and therefore a lower risk of neurosyphilis. However,
in our experience ceftriaxone, also because of its more
convenient applicability once per day, is a suitable alter-
native treatment agent for syphilis especially in HIV in-
fected patients in whom parenteral therapy seems war-
ranted more frequently. However, further prospective
studies are needed to confirm these findings.
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